Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783588 | 0.87 | CES2 (0.39) | CES2CES1 | |
| SCHEMBL3146619 | 0.87 | CES2 (0.39) | CES2CES1 | |
| SCHEMBL4171160 | 0.82 | ADRB2 (0.34) | — | |
| SCHEMBL3132998 | 0.80 | SLC6A2 (0.32) | CES2CES1 | |
| SCHEMBL23231418 | 0.78 | LMNA (0.41) | CES2CES1 | |
| SCHEMBL24013091 | 0.78 | APEX1 (0.40) | — | |
| SCHEMBL30242726 | 0.78 | APEX1 (0.40) | — | |
| SCHEMBL4169011 | 0.74 | CES2 (0.30) | CES2CES1 | |
| SCHEMBL14607861 | 0.73 | CES2 (0.45) | CES2CES1 | |
| SCHEMBL3138467 | 0.73 | CES2 (0.45) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | VORONOI INC. (KR) | 2024-01-25 | — | — | US | disclosed |
| CN-117255792-A | Heteroaryl derivatives, process for preparing the same and pharmaceutical compositions comprising the same as active ingredient | 沃若诺伊公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2022234965-A1 | HETEROARYL DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 보로노이 | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037330-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | CES2 2857/4885CES1 3727/4885 |
| US-20240025888-A1 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | ERBB2, EGFR, ERBB3 | CES2 2857/4885CES1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.